Peptide News Digest

#Oral Peptides

14 stories

Oral peptide formulations have been the long-running drug-delivery challenge in the field. Most peptides degrade in the gut or fail to cross the intestinal epithelium at therapeutic dose. The successful examples — oral semaglutide, oral Wegovy — depend on salt-permeation enhancers like SNAC.

Programmes covered on this site: oral semaglutide and oral Wegovy, Vivtex's permeability platforms, Biocon's oral insulin work, Boehringer's gut-targeted peptide formulations, and the small-molecule oral GLP-1 alternatives (Foundayo / orforglipron) that sidestep the peptide-stability problem altogether.

Stories here cover platform readouts and the partnership deals around them. See #oral-peptide for the singular tag and #drug-delivery for broader delivery technology.

Clinical Trials · View digest

Priavoid's Oral D-Peptide PRI-002 Missed Its Main Alzheimer's Goal at 48 Weeks in the 304-Patient PRImus-AD Trial

In people aged 55 to 80 with mild cognitive impairment or mild dementia due to Alzheimer's, daily PRI-002 at 300 mg or 600 mg did not beat placebo on the CDR-SB scale at week 48, Priavoid said at the CTAD conference in Boston on November 17. The company pointed to trends at week 72, such as 26.7% slower decline on ADAS-Cog13 (p=0.102), but most were not statistically significant. The drug met its safety endpoint. Brain swelling (ARIA-E) occurred in 2% or fewer patients in each group, and small brain bleeds (ARIA-H) in 8% and 11.7% on the two doses versus 5% on placebo, though a safety board stopped close central MRI checks for ARIA after the first 90 patients reached 24 weeks.

Industry · View digest

Ascletis Files a U.S. IND for a Weekly Oral Tablet Combining an Amylin Peptide and a GLP-1/GIP/Glucagon Peptide

Hong Kong-listed Ascletis asked the FDA to begin human testing of ASC36_37o, a tablet pairing its amylin receptor agonist ASC36 with its triple agonist ASC37. In monkeys, the company reported half-lives of up to 200 hours and 96 hours and oral bioavailability above 10% and at least 9.1%. In obese rats, the combination produced about 69% more weight loss than ASC37 alone. A U.S. Phase 1 study of the amylin pill on its own is underway.

Industry · View digest

argenx Agrees to Buy Unnatural Products for $550 Million Upfront and Up to $1.15 Billion to Add Macrocyclic Peptides

argenx will pay $550 million in cash upfront and up to $595 million in development and regulatory milestones for Santa Cruz, California-based Unnatural Products, whose discovery engine designs macrocyclic peptides, small ring-shaped chains of amino acids that can be built to bind disease targets. argenx said in its November 9 announcement that the peptides could support oral or long-acting medicines for immune-mediated diseases alongside its antibody work; the deal is expected to close by the end of 2026.

Clinical Trials · View digest

J&J's Oral Peptide Icotyde Met Its Main Goal in Psoriatic Arthritis, With 58% Reaching ACR20 at Week 16 vs. 41% on Placebo

In the Phase 3 ICONIC-PsA 1 trial (NCT06878404) in adults with active psoriatic arthritis who had not taken a biologic, 58% on once-daily icotrokinra 200 mg reached ACR20 at week 16 vs. 41% on placebo; ACR50 rates were 29% vs. 16% and ACR70 rates 13% vs. 5%, and J&J did not state significance for either. Among patients with enough psoriasis to score, 57% vs. 14% had clear or almost clear skin (nominal p<0.001). J&J announced the late-breaking ACR Convergence 2026 data on November 7; Icotyde, which blocks the IL-23 receptor, is approved in the U.S. for plaque psoriasis but not psoriatic arthritis.

Research · View digest

Genentech Rat Study Sets a Stability Target for Oral Macrocyclic Peptides Given With the Absorption Enhancer Sodium Decanoate

Genentech scientists dosed two series of closely related macrocyclic peptides, which differed mainly in how quickly pancreatic enzymes broke them down, directly into rats' small intestines with and without sodium decanoate (C10), reporting in Molecular Pharmaceutics. C10 protected all the peptides from pancreatic enzymes in a concentration-dependent way in lab tests and raised their absolute bioavailability in rats, and a half-life of about 60 minutes in a pancreatin stability test without C10 was enough for maximal absorption with the enhancer.

Research · View digest

Innsbruck Review Argues 'Dry' Reverse Micelles With Under 1% Water Could Carry Peptide Drugs Through the Gut

Pharmaceutical scientists at the University of Innsbruck in Austria reviewed in Small on October 24, 2026 reverse micelles, tiny droplets with a water-loving core inside an oily shell, as carriers for oral peptide and protein drugs. They argue that newer dry reverse micelles, with internal water below 1%, avoid the instability of older water-rich versions while protecting peptides from digestive enzymes and helping them cross the gut lining. The authors say animal studies show oral bioavailability comparable to or better than other approaches such as hydrophobic ion pairing in selected systems; the paper is a review, not new data.

Research · View digest

Verdiva Bio Brings Oral Amylin VRB-103 and a GLP-1/Amylin Co-Agonist to ADA 2026 With Preclinical Data

Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.

Research · View digest

EPFL Team Builds Membrane-Permeable Cyclic Peptides From Scratch, Targeting a Core Barrier to Oral and Intracellular Peptide Drugs

A study from Christian Heinis's lab, published June 1 in Nature Chemical Biology, screened a library of 15,360 random cyclic peptides for the rare ability to cross cell membranes, then refined a lead (Peptide 30, 890.6 daltons) that blocked the intracellular Keap1-Nrf2 interaction in living cells. By engineering lower charge, fewer hydrogen-bond donors, and smaller polar surface area, the approach reaches targets inside cells without starting from a known ligand, a route toward peptide drugs that can be taken orally.

Industry · View digest

Syneron Bio Closes $150M Series B for Macrocyclic Peptide Discovery Platform, Backed by AstraZeneca and Abu Dhabi's ADIA

Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.

Industry · View digest

AJMC Oral Peptides FAQ Mainstreams the Bioavailability and Safety Conversation Ahead of July PCAC

AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.

Industry · View digest

Oral & Macrocyclic Peptides Summit Opens in San Diego With 66 Approved Cyclic Peptides

The Drug Discovery Chemistry Oral & Macrocyclic Peptides Summit (April 14-15, San Diego) convenes as 66 cyclic peptide drugs have gained global approval and the field races to solve oral bioavailability. Key advances include Chugai's Luna18 achieving 21-47% oral bioavailability and Merck's macrocyclic PCSK9 inhibitor enlicitide delivering injectable-level results in pill form.

Research · View digest

Frontiers Review Maps Challenges and Strategies for Oral Peptide Drug Delivery

A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.